This week's guest is Joseph Ferner of Inpart, the author of a new R&D Trends Report on Immunology and Inflammation. Together we discussed the research landscape The post What’s next in immunology & inflammation R&D: The trends to watch appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provid...| Labiotech.eu
Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi are recognized for their groundbreaking immune system research, highlighting regulatory T cells' roles. The post DAILY DOSE: Immune tolerance pioneers win Nobel Prize for unlocking body’s self-control; When will autonomous AI make Nobel-worthy science? first appeared on Scientific Inquirer.| Scientific Inquirer
Last Friday, the ACIP voted to recommend COVID vaccination “based on individual-based decision-making” for adults 65 and older. For individuals 6 months to 64 years old, the vaccine is recommended based on individual decision, “with an emphasis that the risk-benefit of vaccination is more favorable for individuals who are at an increased risk for severe… The post ACIP recommends COVID vaccine based on “individual decision making” appeared first on Drug Discovery and Development.| Drug Discovery and Development
The ACIP met this week to vote on recommendations for the MMRV, Hepatitis B and COVID vaccines. On Thursday, they voted to recommend separate MMR and varicella vaccines for children under four, instead of the combination MMRV vaccine. On Friday, they voted to table the Hepatitis B decision for another meeting. Also on Friday, the… The post ACIP voted to stop recommending MMRV vaccine for young children appeared first on Drug Discovery and Development.| Drug Discovery and Development
Despite some vocal attacks against vaccines, a poll conducted by Republican pollsters — including Donald Trump’s chief pollster — shows “that there is broad unity across party lines supporting vaccines such as measles (MMR), shingles, tetanus, diphtheria and pertussis (TDAP), and Hepatitis B.” NBC News reported that the poll results were made known to Republican… The post Bipartisan support for vaccines could be a balm for beleaguered vaccine companies appeared first on Drug Disco...| Drug Discovery and Development
On Friday, Kevenue, the maker of Tylenol, saw its stocks drop more than 10% after the Wall Street Journal reported that Health and Human Services Secretary Robert F. Kennedy plans to release a federal report connecting prenatal use of Tylenol to autism. As Kennedy and his appointed vaccine panel continue to erode vaccine recommendations, many… The post Vaccine makers’ stocks continue to spiral as the segment faces fresh pressures appeared first on Drug Discovery and Development.| Drug Discovery and Development
Telomere damage drives T cell exhaustion. Antioxidants restored their cancer-fighting strength in mice. Tumor environments place heavy stress on immune cells that fight cancer. Limited oxygen, elevated acidity, and other harsh conditions overload mitochondria, the cell’s energy producers, which c| SciTechDaily
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.| JNJ.com
Inflammatory bowel disease doesn't have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.| JNJ.com
Freya Cook explores the development of a more effective tuberculosis vaccine and the current challenges researchers face. The post Why don’t we have a good tuberculosis vaccine? appeared first on The Oxford Scientist.| The Oxford Scientist
"These grants highlight The Wertheim UF Scripps Institute’s unique expertise in areas that include neuroscience, immunology, biochemistry, drug discovery and RNA therapeutics,” said Scientific Director Patrick Griffin, Ph.D.| The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Tec...
Pfizer Inc. and BioNTech SE announced today that the FDA has approved their COVID-19 vaccine for adults ages 65 and older and individuals from 5 to 64 years old who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. The approval comes amidst the development of a… The post Pfizer and BioNTech’s COVID vaccine approved for individuals at increased risk appeared first on Drug Discovery and Development.| Drug Discovery and Development
The U.S. Centers for Disease Control and Prevention chose Retsef Levi, a management and health analytics expert at MIT, to lead its COVID-19 immunization workgroup. Levi announced on X that he is “looking forward to working with colleagues… to pursue the truth through science and evidence-based approach.” Levi, one of the eight new ACIP members… The post ACIP’s COVID vaccine workgroup to be headed by vaccine skeptic Retsef Levi appeared first on Drug Discovery and Development.| Drug Discovery and Development
Biotech labs are mining worm chemistry to design medicines that calm the immune system without the risks of live infection.| Freethink
Viruses infect cells with a goal of taking control to churn out new viral copies. Cells have learned to fight back.| The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Tec...
A new study in Nature that finds a gene therapy against HIV given at birth can protect breastfeeding babies from infection with a single dose.| wertheim.scripps.ufl.edu
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language… The post Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classifi...| Drug Discovery and Development
One in five of our faculty holds a prestigious R35 Outstanding Investigator Award from the National Institutes of Health.| wertheim.scripps.ufl.edu
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Marta Reguera Gómez, Ph.D., a postdoctoral associate at the UF College of Dentistry, won first place in the postdoctoral poster competition at EPI Research Day 2025.| epi.ufl.edu
Measles virus (MeV) rides its cellular carriages through the blood vessel networks and lymph node stations, spreading far and wide around the body. But after the journey ends, we're stuck paying its fare. How does that happen?| Virology Down Under
AnaptysBio’s investigational drug rosnilimab has delivered promising Phase 2b trial results for moderate-to-severe rheumatoid arthritis.| Drug Discovery and Development
“One of the UK research system’s strengths is having established processes that allow for this review so that we maintain an accurate and robust research record. Promoting and improving this …| For Better Science
Scripps Research awarded doctoral degrees to 59 graduate students, including eight from its partner program based at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, during its 32nd commencement.| wertheim.scripps.ufl.edu
$1B women's health push and RNAi advances mark JPM 2025, with solid tumor therapies gaining momentum| Drug Discovery and Development
The presence or absence of either specific antibodies or antigens in a sample is measured and detected known as ELISA (Enzyme Linked Immunosorbent Assay).| microbialnotes.com